MY147997A - N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators - Google Patents

N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators

Info

Publication number
MY147997A
MY147997A MYPI20052469A MYPI20052469A MY147997A MY 147997 A MY147997 A MY 147997A MY PI20052469 A MYPI20052469 A MY PI20052469A MY PI20052469 A MYPI20052469 A MY PI20052469A MY 147997 A MY147997 A MY 147997A
Authority
MY
Malaysia
Prior art keywords
androgen
disease
compounds
bone
androgen receptor
Prior art date
Application number
MYPI20052469A
Other languages
English (en)
Inventor
Barbara Hanney
Yuntae Kim
Michael R Krout
Robert S Meissner
Hellen J Mitchell
Jeffrey Musselman
James J Perkins
Jiabing Wang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MY147997A publication Critical patent/MY147997A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI20052469A 2004-06-07 2005-05-31 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators MY147997A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57769804P 2004-06-07 2004-06-07

Publications (1)

Publication Number Publication Date
MY147997A true MY147997A (en) 2013-02-28

Family

ID=35415107

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20052469A MY147997A (en) 2004-06-07 2005-05-31 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators

Country Status (24)

Country Link
US (3) US7268153B2 (2)
EP (1) EP1755572B1 (2)
JP (1) JP4881865B2 (2)
CN (1) CN1976902A (2)
AR (1) AR049140A1 (2)
AT (1) ATE545631T1 (2)
AU (1) AU2005251766B9 (2)
BR (1) BRPI0511862A (2)
CA (1) CA2569124C (2)
CR (1) CR8777A (2)
EC (1) ECSP067061A (2)
IL (1) IL179843A0 (2)
MA (1) MA28677B1 (2)
MX (1) MXPA06014235A (2)
MY (1) MY147997A (2)
NO (1) NO20070085L (2)
NZ (1) NZ551738A (2)
PE (1) PE20060401A1 (2)
RU (1) RU2378255C2 (2)
SG (1) SG169398A1 (2)
TW (1) TW200610755A (2)
UA (1) UA87854C2 (2)
WO (1) WO2005120477A2 (2)
ZA (1) ZA200609673B (2)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
JP2008518968A (ja) * 2004-10-29 2008-06-05 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしてのｎ−（ピリジン−３−イル）−２−フェニルブタンアミド
US20090088458A1 (en) * 2005-08-02 2009-04-02 Meissner Robert S N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
WO2007077510A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
AU2007313295A1 (en) * 2006-10-18 2008-04-24 Merck Sharp & Dohme Corp. 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
EP2222636B1 (en) 2007-12-21 2013-04-10 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
JPWO2009136629A1 (ja) * 2008-05-09 2011-09-08 あすか製薬株式会社 生活習慣病予防・治療剤
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US9763678B2 (en) 2010-06-24 2017-09-19 DePuy Synthes Products, Inc. Multi-segment lateral cage adapted to flex substantially in the coronal plane
FR2982261B1 (fr) * 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CN103288669B (zh) * 2013-07-01 2015-06-24 南开大学 一种阿卓乳酸酰胺衍生物及应用
US9868705B2 (en) 2013-09-27 2018-01-16 The Board Of Trustees Of The University Of Illinois Tetra-aryl cyclobutane inhibitors of androgen receptor action for the treatment of hormone refractory cancer
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
RU2724103C2 (ru) * 2015-04-21 2020-06-22 Джи Ти Икс, ИНК. Селективные лиганды-разрушители андрогенных рецептов (sard) и способы их применения
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3099155A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2020214834A1 (en) 2019-04-19 2020-10-22 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
CA3138197A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20210024636A1 (en) * 2019-07-26 2021-01-28 Chemistryrx Compositions and methods for treating sexual dysfunction
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
MX2023011241A (es) 2021-03-23 2023-10-03 Nuvation Bio Inc Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
JP2024516024A (ja) 2021-05-03 2024-04-11 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
CN113816900B (zh) * 2021-10-18 2024-06-25 宁夏瑞泰科技股份有限公司 一种2-氯-5-甲基吡啶-3-甲醛的合成方法

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809965A (en) * 1956-04-30 1957-10-15 Dow Chemical Co Phthalides
CA777769A (en) 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
FR2531088B1 (fr) 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
GB8332704D0 (en) 1983-12-07 1984-01-11 Pfizer Ltd Growth promotants for animals
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8726179D0 (en) 1987-11-09 1987-12-16 Fujisawa Pharmaceutical Co Heterocyclic derivatives
CA1339805C (en) 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
US4922007A (en) 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5019651A (en) 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5583130A (en) 1992-09-25 1996-12-10 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5317017A (en) 1992-09-30 1994-05-31 Merck & Co., Inc. N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release
US5374721A (en) 1992-10-14 1994-12-20 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
CA2147503A1 (en) 1992-11-06 1994-05-26 Judith M. Pisano Substituted dipeptide analogs promote release of growth hormone
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5284841A (en) 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5430144A (en) 1993-07-26 1995-07-04 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5952281A (en) 1993-08-04 1999-09-14 Colgate Palmolive Company Aqueous cleaning composition which may be in microemulsion form containing a silicone antifoam agent
US5510517A (en) 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
TW257765B (2) 1993-08-25 1995-09-21 Merck & Co Inc
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
HUT75224A (en) 1993-10-19 1997-04-28 Merck & Co Inc Combination of bisphosphonates and growth hormone secretagogues
US5438136A (en) 1993-11-02 1995-08-01 Merck & Co., Inc. Benzo-fused macrocycles promote release of growth hormone
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5494919A (en) 1993-11-09 1996-02-27 Merck & Co., Inc. 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
KR960705808A (ko) 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
WO1995014666A1 (en) 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
AU1371895A (en) 1993-12-13 1995-07-03 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5606054A (en) 1993-12-14 1997-02-25 Merck & Co., Inc. Heterocyclic-fused lactams promote release of growth hormone
WO1995017423A1 (en) 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU683121B2 (en) 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
NZ290008A (en) 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
AU3128195A (en) 1994-07-20 1996-02-16 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US5494920A (en) 1994-08-22 1996-02-27 Eli Lilly And Company Methods of inhibiting viral replication
JPH10504825A (ja) 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
US5736357A (en) 1994-10-27 1998-04-07 Arris Pharmaceutical Cathespin O protease
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
DE19504379A1 (de) * 1995-02-10 1996-08-14 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate sowie sie enthaltende pharmazeutische Präparate
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5710159A (en) 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997001540A1 (en) 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
US6008213A (en) 1995-06-29 1999-12-28 Smithkline Beecham Corporation Integrin receptor antagonists
IL123164A (en) 1995-08-30 2001-03-19 Searle & Co Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
US6204293B1 (en) * 1995-11-06 2001-03-20 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
CZ288545B6 (cs) 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IL125033A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
CZ203898A3 (cs) 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
WO1997024122A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
ES2171768T3 (es) 1996-03-20 2002-09-16 Hoechst Ag Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
KR20000064710A (ko) 1996-03-20 2000-11-06 제넨테크, 인코포레이티드 인테그린, 특히 ανβ3 인테그린에 대하여 특이 활성을갖는 3환식 화합물, 그 제조방법 및 그 제조를 위한 중간체, 의약으로서의 그 용도 및 그를 포함한 약제 조성물
WO1997036858A1 (en) 1996-03-29 1997-10-09 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
DE69706407T2 (de) 1996-03-29 2002-05-29 G.D. Searle & Co., Chicago META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
ES2160949T3 (es) 1996-03-29 2001-11-16 Searle & Co Derivados de fenilen-sulfonamida sustituidos en meta.
DK0894084T3 (da) 1996-03-29 2002-10-14 Searle & Co Kanelsyrederivater og deres anvendelse som integrinantagonister
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
EP0907637A1 (de) 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalanin-derivate als integrin-inhibitoren
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
IL129344A0 (en) 1996-11-27 2000-02-17 Du Pont Pharm Co Novel integrin receptor antagonists
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
DE19705450A1 (de) 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
EP1000031A4 (en) 1997-07-25 2001-08-16 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
AU8689798A (en) 1997-08-04 1999-02-22 Smithkline Beecham Corporation Integrin receptor antagonists
JP2001514253A (ja) 1997-09-04 2001-09-11 スミスクライン・ビーチャム・コーポレイション インテグリンレセプターアンタゴニスト
AR015446A1 (es) 1997-09-19 2001-05-02 Smithkline Beecham Corp Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
AU9578798A (en) 1997-09-24 1999-04-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
CN1273529A (zh) 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
CA2309204A1 (en) 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists
EA003095B1 (ru) 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
CA2315232A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
CA2315370A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
EP0933367A1 (en) 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
WO1999033798A1 (en) 1997-12-25 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
EP0928790B1 (en) 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
SI0928793T1 (en) 1998-01-02 2002-10-31 F. Hoffmann-La Roche Ag Thiazole derivatives
YU47200A (sh) 1998-01-23 2002-11-15 Aventis Pharma Deutschland Gmbh. Novi derivati sulfonamida kao inhibitori koštane resorpcije i kao inhibitori ćelijske adhezije
ZA994406B (en) 1998-03-04 2000-02-11 Searle & Co Meta-azacyclic amino benzoic acid and derivatives thereof.
CN1299282A (zh) 1998-03-10 2001-06-13 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
CN1140511C (zh) 1998-04-09 2004-03-03 明治制果株式会社 作为整合素αvβ3拮抗剂的氨基哌啶衍生物
KR20010042614A (ko) 1998-04-10 2001-05-25 윌리암스 로저 에이 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체
AU3561099A (en) 1998-04-14 1999-11-01 American Home Products Corporation Acylresorcinol derivatives as selective vitronectin receptor inhibitors
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
ATE253061T1 (de) 1998-06-29 2003-11-15 Iaf Biochem Int Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
AU748621B2 (en) 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
AU7278500A (en) * 1999-08-18 2001-03-13 Aventis Cropscience Gmbh Fungicides
WO2001017562A1 (fr) 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
DE60132975T2 (de) 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
EP1272467A4 (en) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
DK1302461T3 (da) * 2000-05-31 2008-01-28 Santen Pharmaceutical Co Ltd TNF-alfa-produktionsinhibitorer
EP1193248A1 (en) 2000-09-30 2002-04-03 Aventis Pharma Deutschland GmbH Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use
US7214690B2 (en) * 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
CA2475108A1 (en) * 2002-02-07 2003-08-14 Mitchell S. Steiner Treating benign prostate hyperplasia with sarms
KR20040104463A (ko) * 2002-02-28 2004-12-10 유니버시티 오브 테네시 리서치 파운데이션 비가역적 선택적 안드로겐 수용체 모듈레이터 및 이를사용하는 방법
CA2484173A1 (en) * 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
EP1562906A4 (en) * 2002-10-15 2009-12-02 Univ Tennessee Res Foundation HETEROCYCLIC SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHOD FOR THEIR USE
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
TW200410921A (en) * 2002-11-25 2004-07-01 Hoffmann La Roche Mandelic acid derivatives
US7217794B2 (en) * 2003-04-02 2007-05-15 Daiamed, Inc. Compounds and methods for treatment of thrombosis
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
EP1477167A1 (en) 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
US7375100B2 (en) * 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
AU2004309357B2 (en) 2003-12-22 2010-10-07 Merck Sharp & Dohme Corp. Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
BRPI0508927A (pt) * 2004-03-17 2007-08-14 Pfizer compostos úteis para o tratamento de doenças
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators

Also Published As

Publication number Publication date
CR8777A (es) 2007-08-28
AR049140A1 (es) 2006-06-28
AU2005251766A1 (en) 2005-12-22
US7268153B2 (en) 2007-09-11
ECSP067061A (es) 2007-01-26
ATE545631T1 (de) 2012-03-15
US7763659B2 (en) 2010-07-27
WO2005120477A2 (en) 2005-12-22
BRPI0511862A (pt) 2008-01-15
RU2378255C2 (ru) 2010-01-10
EP1755572A2 (en) 2007-02-28
IL179843A0 (en) 2007-05-15
MA28677B1 (fr) 2007-06-01
AU2005251766B9 (en) 2009-05-28
NO20070085L (no) 2007-03-06
CA2569124A1 (en) 2005-12-22
TW200610755A (en) 2006-04-01
UA87854C2 (en) 2009-08-25
CN1976902A (zh) 2007-06-06
US20050277681A1 (en) 2005-12-15
RU2006146678A (ru) 2008-07-20
JP2008501800A (ja) 2008-01-24
MXPA06014235A (es) 2007-02-14
JP4881865B2 (ja) 2012-02-22
EP1755572B1 (en) 2012-02-15
US7629367B2 (en) 2009-12-08
CA2569124C (en) 2013-04-23
SG169398A1 (en) 2011-03-30
NZ551738A (en) 2009-11-27
ZA200609673B (en) 2008-09-25
US20070225229A1 (en) 2007-09-27
AU2005251766B2 (en) 2009-01-15
PE20060401A1 (es) 2006-05-15
WO2005120477A3 (en) 2006-03-02
US20080139630A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MY147997A (en) N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200730505A (en) Polymorphs of an androgen receptor modulator
WO2003092588A3 (en) 4-azasteroid derivatives as androgen receptor modulators
WO2005005606A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
GEP20074197B (en) 5ht2c receptor modulators
DE602007008237D1 (de) Benzamidderivate und assoziierte verwendungen
EA200602151A1 (ru) Метаболиты селективных модуляторов андрогеновых рецепторов и способы их применения
IL183565A0 (en) 5ht2c receptor modulator compositions and methods of use
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
UA84146C2 (ru) Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
JO2800B1 (en) Rosaclubta tetrahydrate compounds [B] indole androgen regulators
SI1853266T1 (sl) 2S,4R ketokonazol za zdravljenje diabetesa, metabolnega sindroma in drugih stanj
TW200726462A (en) Benzamide derivatives and uses related thereto
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
WO2008048540A3 (en) 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
ATE373657T1 (de) Androgen-rezeptor-modulatoren und verwendungsverfahren dafür
WO2006026196A3 (en) Androgen receptor modulators
WO2005005380A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
ATE532539T1 (de) Knochenzement und anwendungsverfahren dafür
WO2004100874A3 (en) Androgen receptor modulators and methods of use thereof
WO2005044988A3 (en) 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
WO2005004807A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
WO2005009949A3 (en) 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.